FV-100 explained

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity.^[1] It may be effective against shingles.^[2]

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.^[3]

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. It has reached Phase III clinical trials.^[4]

Notes and References

1. 10.1093/jac/dkp294 . McGuigan, Christopher . Balzarini, Jan . FV100 as a new approach for the possible treatment of varicella-zoster virus infection . . 2009 . 64 . 4 . 671–673 . 19679595. free .
2. Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264.
3. Shows structure of FV100.
4. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747.